Showing results (2061-2070 of 2,436) with videos related to

Sort By:
Pageof 244
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 6, 2022
Concomitant Drugs Prognostic Score in Patients With Metastatic Renal Cell Carcinoma Receiving Ipilimumab and Nivolumab in the Compassionate Use Program in Italy: Brief CommunicationSebastiano Buti, Umberto Basso, Diana Giannarelli, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 30, 2004
Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injuryRiccardo Bertini, Marcello Allegretti, Cinzia Bizzarri, et al.
Frontiers in Immunology|March 12, 2026
Liver metastases in advanced urothelial carcinoma (ARON-2): do pembrolizumab and avelumab make a difference in a poor-prognosis scenario?Linda Cerbone, Giandomenico Roviello, Fabio Calabrò, et al.
The World Allergy Organization Journal|November 17, 2021
ARIA-ITALY multidisciplinary consensus on nasal polyposis and biological treatmentsCarlo Lombardi, Riccardo Asero, Diego Bagnasco, et al.
International Journal of Cancer|November 4, 2025
Toxicity-related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1 study)Javier Molina-Cerrillo, Giandomenico Roviello, Maria T Bourlon, et al.
The Journal of Urology|July 22, 2014
Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinomaMatteo Santoni, Alessandro Conti, Camillo Porta, et al.
Nature Genetics|March 8, 2016
Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinomaXimena Bonilla, Laurent Parmentier, Bryan King, et al.
Plos Genetics|May 3, 2014
Loss of function mutation in the palmitoyl-transferase HHAT leads to syndromic 46,XY disorder of sex development by impeding Hedgehog protein palmitoylation and signalingPatrick Callier, Pierre Calvel, Armine Matevossian, et al.
Immunotherapy|January 20, 2025
Role of Hb to RDW ratio in metastatic renal cell carcinoma patients treated with first-line immunotherapy combinationsMatilde Corianò, Alessandro Lazzarin, Michele Maffezzoli, et al.
Clinical and Experimental Medicine|November 2, 2023
Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 studyMatteo Santoni, Francesco Massari, Hideki Takeshita, et al.
Pageof 244